Understanding how some patients with chronic myeloid leukemia can remain healthy without treatment
Official title: Mechanisms of treatment-free remission in a mouse model of chronic myeloid leukemia
Funded at University of California-Irvine · NIH-11078332 · Data updated 2026-11-12
This study is looking into why some people with chronic myeloid leukemia can stay healthy without taking their medication, using mice to find out what helps them maintain remission, which could lead to better ways to manage the condition and lessen the need for long-term treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California-Irvine NIH-funded |
| Lab location | 1 site (Irvine, United States) |
| Project start | May 1, 2024 |
| Project end | April 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $359,138 |
| NIH project number | 5R01CA280606-02 |
| Project ID | NIH-11078332 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with chronic myeloid leukemia who have achieved molecular remission and are considering stopping their TKI therapy.
✕Less likely to help
Patients who are currently experiencing active CML or have not achieved remission may not benefit from this research.
What this research studies
This research investigates the biological mechanisms that allow some patients with chronic myeloid leukemia (CML) to maintain remission without ongoing treatment. By studying a mouse model, the researchers aim to identify factors that contribute to treatment-free remission, where patients can stop taking tyrosine kinase inhibitors (TKIs) without experiencing a relapse. The study will involve analyzing the behavior of leukemic stem cells and their interactions within the body to uncover why some patients can remain healthy without medication. This could lead to new strategies for managing CML and reducing the need for long-term drug therapy.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that allow CML patients to maintain remission without the side effects and costs associated with long-term medication.
How similar studies have gone: While there have been studies on treatment-free remission in CML, this research aims to explore novel biological mechanisms that have not been fully understood, making it a potentially groundbreaking approach.
Where this research is happening
-
University of California-Irvine
Irvine, United States Active
Researchers
- Principal investigator: Van Etten, Richard a. — University of California-Irvine
- Study coordinator: Van Etten, Richard a.
Related research
Other NIH-funded projects on the same topics.
-
Chronic myeloid leukemia: how T cells and leukemia stem cells interact during treatment
This NIH grant explores how immune cells and stubborn leukemia stem cells interact during therapy to better predict if patients can stay off treatment.
-
Targeting DYRK2 to kill leukemia stem cells in CML
Aims to find ways to remove leukemia stem cells in chronic myeloid leukemia by boosting a protein (DYRK2) that can halt their growth.
-
Why chronic myeloid leukemia sometimes resists treatment and how to improve TKI care
This project looks at why some people with chronic myeloid leukemia respond differently to tyrosine kinase inhibitor drugs and aims to help more patients get deeper, longer-lasting remissions.
-
Targeting a specific protein to eliminate leukemia stem cells in chronic myeloid leukemia.
This study is looking at a new way to help people with chronic myeloid leukemia (CML) by focusing on a protein called DYRK2, which could help make leukemia stem cells less likely to survive, so patients might be able to stop their current treatments without their cancer coming back.
-
Improving treatment for chronic myeloid leukemia with targeted therapies
This study is looking for ways to help people with chronic myeloid leukemia (CML) respond better to their main treatment, tyrosine kinase inhibitors (TKIs), especially during the first year after they are diagnosed, so that more patients can achieve a lasting remission and possibly a cure.
-
Targeting a specific protein to treat chronic myeloid leukemia
This study is testing a new small protein that could help stop a key protein linked to chronic myeloid leukemia from working against you, and if it works, it might offer a fresh treatment option for patients like you.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.